Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.35 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.32 |
| ▸ | BTK | Q06187 | 3/20 | 0.32 |
| ▸ | JAK1 | P23458 | 3/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269223 | 0.94 | PIK3CD (0.34) | PIK3CDBTKJAK1CNR1CNR2 | |
| SCHEMBL31269058 | 0.91 | PIK3CD (0.36) | PIK3CDIP6K1JAK1CNR1CNR2 | |
| SCHEMBL31269146 | 0.90 | PIK3CD (0.35) | PIK3CDBTKJAK1CNR1CNR2 | |
| SCHEMBL31268954 | 0.90 | PIK3CD (0.35) | PIK3CDJAK1KDM4E | |
| SCHEMBL31269478 | 0.90 | SYK (0.36) | PIK3CDSCN9A | |
| SCHEMBL31268754 | 0.90 | PIK3CD (0.34) | PIK3CDJAK1CNR1CNR2KDM4E | |
| SCHEMBL31269040 | 0.90 | PIK3CD (0.33) | PIK3CDJAK1CNR1CNR2KDM4E | |
| SCHEMBL31269098 | 0.89 | PIK3CD (0.35) | PIK3CDJAK1CNR1CNR2KDM4E | |
| SCHEMBL31269195 | 0.89 | ABL1 (0.36) | PIK3CDCNR1CNR2WDR5 | |
| SCHEMBL31269443 | 0.89 | ACSS2 (0.34) | PIK3CDJAK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |